Table 1.
General characteristics of the included 15 guidelines‡‡
| Guidelines identifier, Year † |
Organization(s) responsible for guidelines development |
Region | Target population | COI appraisal (RIGHT) ‡ | Proportion of panel members§ | AGREE II score (%) | Guideline status |
|---|---|---|---|---|---|---|---|
| ADA, 2019 | American Diabetes Association | USA | DM | DADG, DCEM, DTCG, DRFG | 14/23 | 69 | Strongly recommended |
| AACE, 2015 | American Association of Clinical Endocrinologists | USA. | DM | DADG, DCEM, DTCG | 30/35 | 63 | Strongly recommended |
| ESC/EASD, 2019 | European Society of Cardiology and European Association for the Study of Diabetes | Europe | DM and pre‐DM | DADG, DCEM, DTCG | 128/150 | 75 | Strongly recommended |
| ESC, 2017 | European Society of Cardiology | Europe | CAD | DADG, DCEM, DTCG | 121/140 | 68 | Strongly recommended |
| ESC, 2016 | European Society of Cardiology | Europe | General population | DADG, DCEM, DTCG | 85/124 | 71 | Strongly recommended |
| ESC, 2015 | European Society of Cardiology | Europe | NSTE‐ACS | DADG, DCEM, DTCG | 100/119 | 66 | Recommended |
| NICE, 2015 | National Institute for Health and Clinical Excellence | UK | T2DM | DADG, DCEM, DTCG | 9/14 | 73 | Strongly recommended |
| SIGN, 2010 | Scottish Intercollegiate Guidelines Network | UK | DM | – | – | 63 | Strongly recommended |
| CDA, 2018 | Canadian Diabetes Association | Canada | DM | DADG, DCEM, DTCG | 80/168 | 73 | Strongly recommended |
| CCS, 2011 | Canadian Cardiovascular Society | Canada | ASCVD | DADG, DTCG | 12/12 | 69 | Strongly recommended |
| RACGP, 2016 | Royal Australian College of General Practitioners | Australia | T2DM | – | – | 48 | Recommended |
| Baker IDI, 2015 | Baker Heart and Diabetes Institute | Australia | T2DM | DADG, DCEM | 50/83 | 64 | Strongly recommended |
| JDS, 2016 | Japan Diabetes Society | Japan | DM | – | – | 42 | Recommended |
| KDA, 2015 | Korean Diabetes Association | Korea | DM | – | – | 36 | Recommended |
| IDF, 2012 | International Diabetes Federation | International | T2DM | – | – | 57 | Recommended |
Proportion of panel members who reported industry relationships.
ASCVD, arteriosclerotic cardiovascular disease; DADG, disclosure of how to access the declarations on the guideline; CAD, coronary artery disease; DCEM, describe how conflicts of interest were evaluated and managed; DM, diabetes mellitus; DRFG, disclosure the role of funder(s) in the different stages of guideline development; DTCG, disclosure the types of conflicts of interest (financial and nonfinancial) that are relevant to the guidelines development; NSTE‐ACS, non‐ST‐elevation acute coronary syndrome; T2DM, type 2 diabetes mellitus.
The guideline references are listed in Table S5 (Supplementary Materials).
The conflicts of interest (COI) of guidelines was evaluated using the Reporting Item for Practice
Guidelines in Healthcare (RIGHT) checklist.